GlassScriptPhysician profile
George J Urban
NPI 1639161524
$258,387.43
in general payments reported to CMS, 2019-2025
39 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $59K · 2021: $51K · 2022: $29K · 2023: $8,796 · 2024: $4,044 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $24K · Food and Beverage: $8,795 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,100 · Travel and Lodging: $3,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $24,338.00 |
| Food and Beverage | $8,794.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,100.00 |
| Travel and Lodging | $3,394.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72,618.66 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Allergan, INC. | $43,804.11 | 2019-2022 | |
| Amgen INC. | $40,393.35 | 2019-2024 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $28,639.91 | 2019-2025 | Ajovy, Austedo Xr |
| Abbvie INC. | $26,242.25 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Axsome Therapeutics, INC. | $24,901.64 | 2025 | Symbravo |
| Impel Pharmaceuticals LLC | $4,811.47 | 2025 | Trudhesa, Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $4,001.12 | 2022 | |
| Lundbeck LLC | $2,825.46 | 2019-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $2,264.09 | 2020-2021 | |
| Tonix Medicines, INC. | $1,756.97 | 2024-2025 | Zembrace Symtouch |
| Pfizer INC. | $1,227.99 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $585.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $446.95 | 2020-2023 | Belsomra |
| Impel Pharmaceuticals INC. | $438.16 | 2022-2023 | Trudhesa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Urban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.